Skip to main content
Respirology Case Reports logoLink to Respirology Case Reports
. 2024 Feb 1;12(2):e01287. doi: 10.1002/rcr2.1287

Pneumonia due to Achromobacter xylosoxidans with a chronic course resembling non‐tuberculous mycobacterial infection

Tomoko Kotani 1, Toshiaki Inazaki 1, Hajime Kasai 1,2,3,4,, Shintaro Rakuman 1, Kenichi Suzuki 1, Takashi Urushibara 1
PMCID: PMC10831394  PMID: 38314101

Abstract

Achromobacter xylosoxidans is a common bacterium that rarely causes pneumonia. Determining whether A. xylosoxidans is the cause of lung infection in patients suspected of having chronic infectious lung disease is challenging because it can present with colonization. We report a case of a 56‐year‐old immunocompetent woman suspected of having non‐tuberculous mycobacteria (NTM) infection on imaging examination and monitored for 3 years. Sputum examinations revealed A. xylosoxidans several times, and it was determined to be a colonization. A. xylosoxidans was isolated from bronchial lavage fluid and aspirated sputum, but no evidence of NTM was observed. She was diagnosed with A. xylosoxidans infection and given ceftazidime for 2 weeks. Her symptoms and imaging findings improved rapidly after treatment, without recurrences. A. xylosoxidans rarely causes chronic lower respiratory tract infections similar to NTM in immunocompetent patients. A. xylosoxidans may be a target for treatment when detected in lower respiratory tract specimens.

Keywords: Achromobacter xylosoxidans, antibiotics, chronic pneumonia, colonization, non‐tuberculosis mycobacterium


Herein, we present a case of pneumonia caused by A. xylosoxidans that exhibited a chronic progression similar to that of non‐tuberculous mycobacteria (NTM) infections.

graphic file with name RCR2-12-e01287-g003.jpg

INTRODUCTION

Achromobacter xylosoxidans is a gram‐negative bacterium usually found in bodies of water. 1 It frequently causes acute infections, including those related to catheter use and pneumonia, particularly during hospitalization. 2 Although multiple cases of infection have been reported in patients with cystic fibrosis (CF), cases of long‐term lung infections in individuals with other lung diseases are rarely documented. 3 Various antibacterial drugs, such as ceftazidime and levofloxacin, are used in the treatment of A. xylosoxidans infections. 4 However, a standardized treatment protocol for A. xylosoxidans infection has not yet been established.

Herein, we present a case of pneumonia caused by A. xylosoxidans that exhibited a chronic progression similar to that of non‐tuberculous mycobacteria (NTM) infections.

CASE REPORT

A 56‐year‐old woman with haemoptysis visited our hospital in January 20XX. Chest computed tomography (CT) revealed bronchiectasis and a small nodular shadow and infiltrative shadows along the airways, mainly in the bilateral lower lobes (Figure 1A). She had a history of pleurisy when she was 42 years old. She has no prior remarkable medical history that suggests immunodeficiency. As an NTM infection was suspected, the patient underwent bronchoscopy. However, acid‐fast bacteria were not detected from sputum obtained from the bronchi. A. xylosoxidans was detected in the general bacterial culture of the same specimen (100 colonies). She was monitored through multiple sputum examinations for acid‐fast bacterium sputum, but no acid‐fast bacterium was detected. Sputum examination for general bacteria was performed once a year over a 3‐year period, which revealed A. xylosoxidans (Geckler 5, 10 colonies). A. xylosoxidans has been rarely reported to cause chronic infection, and the patient did not have any respiratory symptoms other than haemoptysis. No other findings suggest acute respiratory tract infection. Thus, we considered it a colonization.

FIGURE 1.

FIGURE 1

(A) Chest computed tomography (CT) revealed bronchiectasis and a small nodular shadow along the airways in both lungs at the first visit. (B) Chest CT before introduction of ceftazidime (CAZ) shows multiple nodules and consolidations in addition to a gradual exacerbation of the bronchiectasis and small nodular shadow along the airway in both lungs, which were detected 3 years ago. (C) Four weeks after the administration of CAZ, the nodular and infiltrative shadows decreased. (D) Two and a half months later, these findings had further improved.

In January 20XX + 3, her symptoms, including cough and sputum, gradually worsened without any triggers such as upper respiratory tract infections. During a routine visit, chest radiography revealed worsening of the shadows in the lungs (Figure 2). Chest CT also showed a new shadow, in addition to the gradual exacerbation of the pre‐existing shadow (Figure 1B). Because of suspicion of NTM exacerbation, she was admitted for bronchoscopy to identify the species of NTM. On admission, the patient's weight and height were 37 kg and 156 cm, respectively. Her vital signs were normal, except for a low‐grade fever. Chest auscultation revealed coarse bilateral crackles in the thorax. The patient had no disease suggestive of immunosuppression. The patient was not exposed to any soil that could have triggered an NTM infection. She had also no contact, in the form of activities related to occupation, hobbies, or other reasons, with bodies of water that appeared to be contaminated by A. xylosoxidans. Furthermore, she was not a medical professional and had no history of prolonged hospitalization. Blood tests revealed a mild increase in C‐reactive protein (2.00 mg/dL). The immunoglobulin levels were within the normal range, and human immunodeficiency virus infection was negative. Bronchoscopy revealed excessive yellowish white sputum in the left bronchi (Figure 2). A. xylosoxidans was detected in the bronchial lavage fluid (2+) and in the aspirated sputum (1+). However, no acid‐fast bacteria were detected in these samples. She was diagnosed with chronic A. xylosoxidans infection. Antimicrobial therapy with ceftazidime (2 g/day) was administered via continuous infusion for 14 days, followed by oral erythromycin 200 mg/day as a low‐dose macrolide. After ceftazidime administration, her symptoms and imaging findings improved rapidly and did not worsen for 5 months after discontinuation of ceftazidime (Figures 1C,D and 2).

FIGURE 2.

FIGURE 2

Clinical course of the patient. BF, bronchoscopy; CAZ, ceftazidime; Lt, left.

DISCUSSION

The present case presents two notable clinical findings. First, A. xylosoxidans causes chronic pulmonary infections. Second, general bacterial culture might be important even for patients with imaging findings and progression similar to NTM because there could be patients with chronic infection mimicking A. xylosoxidans infection.

A. xylosoxidans has emerged as a potential causative agent of chronic pulmonary infections, even in individuals without CF. Notably, A. xylosoxidans‐induced pneumonia is uncommon in adults without systemic or airway immunodeficiencies. 3 In our review of previously reported cases similar to ours, we identified six cases of pneumonia with A. xylosoxidans (Table 1). 5 , 6 , 7 , 8 , 9 , 10 These cases, along with our case, primarily involved relatively young patients (median age, 52.5 years; range, 45–76 years), with no sex disparity (men/women, 3:4). Bronchiectasis emerged as a prevalent comorbidity (four cases, 57%). A. xylosoxidans was most commonly detected in the bronchoalveolar lavage fluid (five cases, 71%), but some were detected in sputum (two cases, 29%). Although various antibiotics, such as ceftazidime, carbapenem, and quinolones, were used, the antimicrobial sensitivity for A. xylosoxidans was good in all cases. Typically, treatment durations extend to approximately 2 weeks, yielding relatively positive prognoses.

TABLE 1.

Previously reported cases of pneumonia with Achromobacter xylosoxidans (5–10).

No Report (year) Age Sex Clinical syndrome Comorbid conditions Isolation specimen Drug sensitivity Antibiotic of choice Drug use period (days)
1 Chandrasekaran et al. (2012) NA NA Pneumonia Colon cancer Tracheal aspirate Ceftazidime, piperacillin/tazobactam, cefoperazone‐sulbactam, levofloxacin, imipenem, meropenem, tigecycline PIPC/TAZ 14
2 Atalay et al. (2012) 50 Female Pneumonia Adrenal insufficiency, caused by pneumonia BAL Ceftazidime, ciprofloxacin, ofloxacin, piperacillin/tazobactam, cefoperazone/sulbactam CPFX 14
3 Karanth et al. (2014) 55 Male Bronchial pneumonia Bronchiectasis BAL NA NA NA
4 Bharadiya et al. (2014) 48 Male Pneumonia History of tuberculosis Sputum Meropenem, imipenem, piperacillin, ticarcillin, trimethoprim‐sulfamethoxazole, third‐generation cephalosporins MEPM 14
5 Awadh et al. (2017) 45 Female Pneumonia Bronchiectasis, asthma, gastroesophageal reflux disease BAL Amikacin, cefepime, ceftazidime, gentamicin, levofloxacin, meropenem, piperacillin/tazobactam, tobramycin, trimethoprim/sulfamethoxazole LVFX 42
6 Stepman et al. (2020) 76 Female Pneumonia MAI‐colonization, bronchiectasis BAL Tobramycin, amikacin, piperacillin/tazobactam, meropenem MEPM 14
7 Present case 56 Female Pneumonia Bronchiectasis Sputum BAL Piperacilin, ceftazidime, imipenem/cilastatin, meropenem, minocycline, levofloxacin, trimethoprim/sulfamethoxazole CAZ 14

Abbreviations: BAL, bronchial lavage; CAZ, ceftazidime; CPFX, ciprofloxacin; LVFX, levofloxacin; MAC, Mycobacterium avium complex; MAI, mycobacterium avium‐intracellulare; MEPM, meropenem; NA, not applicable; PIPC/TAZ, Piperacillin/Tazobactam.

Determining whether A. xylosoxidans detected in airway specimens is the cause of lung infection in patients suspected of having chronic infectious lung disease can be challenging because it can cause colonization. A. xylosoxidans have imaging findings similar to those of NTM infections. In the present case, although the patient was suspected to have NTM based on CT results, acid‐fast bacteria were not detected in the sputum or bronchial suction phlegm. In contrast, A. xylosoxidans persisted from the initial bronchoscopy. The number of cultured colonies also increased. As a result, a diagnosis of A. xylosoxidans infection was reached, and ceftazidime administration for 2 weeks improved the symptoms and imaging findings. Chronic infection with A. xylosoxidans should be considered in cases of suspected chronic airway infection in which NTM is not detected in multiple airway specimens.

In conclusion, A. xylosoxidans rarely cause chronic lower respiratory tract infections in patients with background lung disease. A. xylosoxidans may be a target for treatment when detected in the lower respiratory tract specimens after 2 weeks of ceftazidime administration.

AUTHOR CONTRIBUTIONS

Dr. Kotani is the guarantor of this manuscript and contributed to the writing and review of the entire manuscript. Drs. Kasai, Suzuki, and Urushibara critically reviewed the manuscript. Drs. Inazaki and Rakuman collected and analysed the clinical data of the patients and critically reviewed the manuscript.

CONFLICT OF INTEREST STATEMENT

None declared.

ETHICS STATEMENT

Appropriate written informed consent was obtained from the patient for the publication of this case report and the accompanying images.

Kotani T, Inazaki T, Kasai H, Rakuman S, Suzuki K, Urushibara T. Pneumonia due to Achromobacter xylosoxidans with a chronic course resembling non‐tuberculous mycobacterial infection. Respirology Case Reports. 2024;12(2):e01287. 10.1002/rcr2.1287

Associate Editor: Young Ae Kang

DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

REFERENCES

  • 1. Spear JB, Fuhrer J, Kirby BD. Achromobacter xylosoxidans (Alcaligenes xylosoxidans subsp. xylosoxidans) bacteremia associated with a well‐water source: case report and review of the literature. J Clin Microbiol. 1988;26:598–599. 10.1128/jcm.26.3.598-599.1988 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Duggan JM, Goldstein SJ, Chenoweth CE, Kauffman CA, Bradley SF. Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Clin Infect Dis. 1996;23:569–576. 10.1093/clinids/23.3.569 [DOI] [PubMed] [Google Scholar]
  • 3. De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros. 2007;6:75–78. 10.1016/j.jcf.2006.05.011 [DOI] [PubMed] [Google Scholar]
  • 4. Bonis BM, Hunter RC. JMM profile: Achromobacter xylosoxidans: the cloak‐and‐dagger opportunist. J Med Microbiol. 2022;71:1505. 10.1099/jmm.0.001505 [DOI] [PubMed] [Google Scholar]
  • 5. Chandrasekaran R, Mac Aogáin M, Chalmers JD, Elborn SJ, Chotirmall SH. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulm Med. 2018;18:83. 10.1186/s12890-018-0638-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Atalay S, Ece G, Samlioğlu P, Kose S, Maras G, Gonullu M. Clinical and microbiological evaluation of eight patients with isolated Achromobacter xylosoxidans . Scand J Infect Dis. 2012;44:798–801. 10.3109/00365548.2012.664780 [DOI] [PubMed] [Google Scholar]
  • 7. Karanth SS, Gupta A, Prabhu M. Community acquired bilateral upper lobe pneumonia with acute adrenal insufficiency: a new face of Achromobacter xylosoxidans . Australas Med J. 2012;5:531–533. 10.4066/AMJ.2012.1279 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Aundhakar S, Mane M, Bharadiya A, Pawar SK. Watch out! Pneumonia secondary to Achromobacter denitrificans . Ann Med Health Sci Res. 2014;4(Suppl. 1):S22–S24. 10.4103/2141-9248.131700 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Awadh H, Mansour M, Aqtash O, Shweihat Y. Pneumonia due to a rare pathogen: Achromobacter xylosoxidans, subspecies denitrificans . Case Rep Infect Dis. 2017;2017:3969682. 10.1155/2017/3969682 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Stepman G, Dabb K, Khan IA, Young JT, Frunzi J. Bilateral pneumonia in a patient with chronic bronchiectasis caused by Achromobacter xylosoxidans subspecies denitrificans. Cureus. 2020;12:e7381. 10.7759/cureus.7381 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.


Articles from Respirology Case Reports are provided here courtesy of Wiley

RESOURCES